Your browser doesn't support javascript.
loading
Non-invasive brain stimulation and neuroenhancement.
Antal, Andrea; Luber, Bruce; Brem, Anna-Katharine; Bikson, Marom; Brunoni, Andre R; Cohen Kadosh, Roi; Dubljevic, Veljko; Fecteau, Shirley; Ferreri, Florinda; Flöel, Agnes; Hallett, Mark; Hamilton, Roy H; Herrmann, Christoph S; Lavidor, Michal; Loo, Collen; Lustenberger, Caroline; Machado, Sergio; Miniussi, Carlo; Moliadze, Vera; Nitsche, Michael A; Rossi, Simone; Rossini, Paolo M; Santarnecchi, Emiliano; Seeck, Margitta; Thut, Gregor; Turi, Zsolt; Ugawa, Yoshikazu; Venkatasubramanian, Ganesan; Wenderoth, Nicole; Wexler, Anna; Ziemann, Ulf; Paulus, Walter.
Afiliação
  • Antal A; Department of Neurology, University Medical Center, Göttingen, Germany.
  • Luber B; Noninvasive Neuromodulation Unit, Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, Bethesda, MD, USA.
  • Brem AK; University Hospital of Old Age Psychiatry, University of Bern, Bern, Switzerland.
  • Bikson M; Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
  • Brunoni AR; Biomedical Engineering at the City College of New York (CCNY) of the City University of New York (CUNY), NY, USA.
  • Cohen Kadosh R; Departamento de Clínica Médica e de Psiquiatria, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Dubljevic V; Service of Interdisciplinary Neuromodulation (SIN), Laboratory of Neurosciences (LIM-27), Institute of Psychiatry, Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Brazil.
  • Fecteau S; School of Psychology, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, UK.
  • Ferreri F; Science, Technology and Society Program, College of Humanities and Social Sciences, North Carolina State University, Raleigh, NC, USA.
  • Flöel A; Department of Psychiatry and Neurosciences, Faculty of Medicine, Université Laval, CERVO Brain Research Centre, Centre intégré universitaire en santé et services sociaux de la Capitale-Nationale, Quebec City, Quebec, Canada.
  • Hallett M; Unit of Neurology, Unit of Clinical Neurophysiology, Study Center of Neurodegeneration (CESNE), Department of Neuroscience, University of Padua, Padua, Italy.
  • Hamilton RH; Department of Clinical Neurophysiology, Kuopio University Hospital, University of Eastern Finland, Kuopio, Finland.
  • Herrmann CS; Department of Neurology, Universitätsmedizin Greifswald, 17475 Greifswald, Germany.
  • Lavidor M; German Centre for Neurodegenerative Diseases (DZNE) Standort Greifswald, 17475 Greifswald, Germany.
  • Loo C; Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
  • Lustenberger C; Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.
  • Machado S; Experimental Psychology Lab, Department of Psychology, Carl von Ossietzky Universität, Oldenburg, Germany.
  • Miniussi C; Department of Psychology and the Gonda Brain Research Center, Bar Ilan University, Israel.
  • Moliadze V; School of Psychiatry and Black Dog Institute, University of New South Wales; The George Institute; Sydney, Australia.
  • Nitsche MA; Neural Control of Movement Lab, Institute of Human Movement Sciences and Sport, Department of Health Sciences and Technology, ETH Zurich, 8092 Zurich, Switzerland.
  • Rossi S; Department of Sports Methods and Techniques, Federal University of Santa Maria, Santa Maria, Brazil.
  • Rossini PM; Laboratory of Physical Activity Neuroscience, Neurodiversity Institute, Queimados-RJ, Brazil.
  • Santarnecchi E; Center for Mind/Brain Sciences - CIMeC and Centre for Medical Sciences - CISMed, University of Trento, Rovereto, Italy.
  • Seeck M; Institute of Medical Psychology and Medical Sociology, University Medical Center Schleswig Holstein, Kiel University, Kiel, Germany.
  • Thut G; Department Psychology and Neurosciences, Leibniz Research Centre for Working Environment and Human Factors at TU, Dortmund, Germany.
  • Turi Z; Dept. Neurology, University Medical Hospital Bergmannsheil, Bochum, Germany.
  • Ugawa Y; Siena Brain Investigation and Neuromodulation Lab (Si-BIN Lab), Unit of Neurology and Clinical Neurophysiology, Department of Medicine, Surgery and Neuroscience, University of Siena, Italy.
  • Venkatasubramanian G; Department of Neuroscience and Neurorehabilitation, Brain Connectivity Lab, IRCCS-San Raffaele-Pisana, Rome, Italy.
  • Wenderoth N; Precision Neuroscience and Neuromodulation Program, Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Wexler A; Department of Clinical Neurosciences, Hôpitaux Universitaires de Genève, Switzerland.
  • Ziemann U; Centre for Cognitive Neuroimaging, School of Psychology and Neuroscience, EEG & Epolepsy Unit, University of Glasgow, United Kingdom.
  • Paulus W; Department of Neuroanatomy, Institute of Anatomy and Cell Biology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Clin Neurophysiol Pract ; 7: 146-165, 2022.
Article em En | MEDLINE | ID: mdl-35734582
ABSTRACT
Attempts to enhance human memory and learning ability have a long tradition in science. This topic has recently gained substantial attention because of the increasing percentage of older individuals worldwide and the predicted rise of age-associated cognitive decline in brain functions. Transcranial brain stimulation methods, such as transcranial magnetic (TMS) and transcranial electric (tES) stimulation, have been extensively used in an effort to improve cognitive functions in humans. Here we summarize the available data on low-intensity tES for this purpose, in comparison to repetitive TMS and some pharmacological agents, such as caffeine and nicotine. There is no single area in the brain stimulation field in which only positive outcomes have been reported. For self-directed tES devices, how to restrict variability with regard to efficacy is an essential aspect of device design and function. As with any technique, reproducible outcomes depend on the equipment and how well this is matched to the experience and skill of the operator. For self-administered non-invasive brain stimulation, this requires device designs that rigorously incorporate human operator factors. The wide parameter space of non-invasive brain stimulation, including dose (e.g., duration, intensity (current density), number of repetitions), inclusion/exclusion (e.g., subject's age), and homeostatic effects, administration of tasks before and during stimulation, and, most importantly, placebo or nocebo effects, have to be taken into account. The outcomes of stimulation are expected to depend on these parameters and should be strictly controlled. The consensus among experts is that low-intensity tES is safe as long as tested and accepted protocols (including, for example, dose, inclusion/exclusion) are followed and devices are used which follow established engineering risk-management procedures. Devices and protocols that allow stimulation outside these parameters cannot claim to be "safe" where they are applying stimulation beyond that examined in published studies that also investigated potential side effects. Brain stimulation devices marketed for consumer use are distinct from medical devices because they do not make medical claims and are therefore not necessarily subject to the same level of regulation as medical devices (i.e., by government agencies tasked with regulating medical devices). Manufacturers must follow ethical and best practices in marketing tES stimulators, including not misleading users by referencing effects from human trials using devices and protocols not similar to theirs.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article